Generate Biomedicines (NASDAQ:GENB) Shares Gap Down – Here’s Why

Generate Biomedicines Inc (NASDAQ:GENB)’s share price gapped down prior to trading on Monday . The stock had previously closed at $16.00, but opened at $15.25. Generate Biomedicines shares last traded at $13.7710, with a volume of 347,864 shares changing hands.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GENB. Morgan Stanley increased their price target on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday. HC Wainwright upped their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Piper Sandler assumed coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price target on the stock. Wall Street Zen downgraded Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Zacks Research raised Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Generate Biomedicines Stock Down 19.2%

The company’s 50-day simple moving average is $12.95.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.